PHARNEXT: Information relating to the total number of voting rights and shares making up the share capital and the par value of the shares – 03/01/2024 at 6:00 p.m.

PARIS, France, 1


March 2024 at 6 p.m. (CET) – Pharnext SCA (FR001400N1P4 – ALPHA)

(the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative diseases without satisfactory therapeutic solutions, presents the number of shares and voting rights making up the share capital, in accordance with the provisions of article L.233-8 II of the Commercial Code and article 223-16 of the General Regulations of the Financial Markets Authority.


Number of shares making up the capital

Number of GROSS voting rights

Number of NET voting rights





Furthermore, the company recalls that, since 1


January 2024, the number of shares issued each month by the company breaks down as follows:





Number of OCEANEs converted

Number of actions created

Number of BSAs



Number of actions created

Before regrouping

January 2024





After grouping

February 2024





The number of newly issued shares in respect of conversions as well as the total number of shares in circulation are kept on the Company’s website: HERE

Warning :

The company Pharnext has set up (i) financing in the form of OCEANE-BSA with the company Global Tech Opportunities 13, which, after having received the shares resulting from the conversion or exercise of these instruments, has not not intended to remain a shareholder of the company, and (ii) financing in OS which were then transferred to a trust, which is now responsible for their equitization.

The shares resulting from the conversion or exercise of the above-mentioned securities are generally sold in the market at very short notice, which can create strong downward pressure on the share price. In the specific case of the trust, the shares are sold on the market according to the terms set out in the trust agreement.

Shareholders may suffer a loss of their invested capital due to a significant decrease in the value of the company’s stock, as well as significant dilution due to the number of securities issued to the company Global Tech Opportunities 13 and/or trust.

Investors are advised to be very vigilant before making the decision to invest (or remain invested) in the securities of the company admitted to trading which carries out such dilutive financing transactions, particularly when they are carried out successively. The company recalls that this dilutive financing operation is not the first that it has implemented.

About Pharnext

Pharnext is a late-stage clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases currently without satisfactory therapeutic solutions. Pharnext has a new drug candidate, PXT3003, in development for Charcot-Marie-Tooth disease type 1A (CMT1A), a rare and debilitating hereditary peripheral neuropathy. PXT3003 benefits from orphan drug status in Europe and the United States. More information on

Pharnext is listed on the Euronext Growth market in Paris (ISIN code: FR001400N1P4).


Financial Press Relations

NEWS finance & communication

Anne-Charlotte Dudicourt

[email protected]

+33 (0)1 53 67 36 32

Investor Relations

NEWS finance & communication

Jérôme Fabreguettes Leib

[email protected]

+33 (0)1 53 67 36 78


Consolidation by exchange of 10,000 old shares for 1 new share

This publication has the “🔒 Actusnews SECURITY MASTER” service.



– To control this key:

Regulated information:

Total number of voting rights and capital:

– Information relating to the total number of voting rights and shares making up the capital

Full and original press release in PDF format:

© Copyright Actusnews Wire

Receive future company press releases free of charge by email by subscribing to

Source link -86